Active, not recruitingEarly Phase 1NCT03893487
Fimepinostat in Treating Brain Tumors in Children and Young Adults
Studying Anaplastic astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sabine Mueller, MD, PhD
- Principal Investigator
- Sabine Mueller, MD, PhDUniversity of California, San Francisco
- Intervention
- Fimepinostat(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 3-39 years · All sexes
- Timeline
- 2019 – 2027
Study locations (19)
- Children's Hospital Los Angeles (CHLA), Los Angeles, California, United States
- Rady Children's Hospital, San Diego, California, United States
- University of California, San Francisco, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan Hospital, Ann Arbor, Michigan, United States
- Children's Minnesota Research Institute, Minneapolis, Minnesota, United States
- Washington University in St Louis, St Louis, Missouri, United States
- Nationwide Children's, Columbus, Ohio, United States
- Oregon Health and Science University, Portland, Oregon, United States
- Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States
- +4 more locations on ClinicalTrials.gov
Collaborators
Pediatric Neuro-Oncology Consortium · Cannonball Kids' Cancer Foundation · Curis, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03893487 on ClinicalTrials.govOther trials for Anaplastic astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNCT07448480Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant GliomasBlokhin's Russian Cancer Research Center
- RECRUITINGEARLY PHASE1NCT06333899Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK FusionNationwide Children's Hospital
- RECRUITINGPHASE1, PHASE2NCT05956821Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of AgeUniversity of Miami
- ACTIVE NOT RECRUITINGPHASE1NCT06614855A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant GliomaJames Markert, MD
- RECRUITINGPHASE2NCT06161974Study of Olutasidenib and Temozolomide in HGGRigel Pharmaceuticals
- RECRUITINGPHASE2NCT05843253Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantNationwide Children's Hospital
- RECRUITINGNCT05839379Targeted Pediatric High-Grade Glioma TherapyNationwide Children's Hospital
- RECRUITINGPHASE2NCT06264388DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaAshish Shah